References
- Garraway WM, Russell EBA, Lee RJ, Collins GN, McKelvie GB, Hehir M, Rogers ACN, Simpson RJ: Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318–321.
- Tammela TL, Kontturi MJ: Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993; 149: 342–344.
- Steiner JF: Finasteride: a 5 alpha-reductase inhibitor. Clin Pharm 1993; 12: 15–23.
- Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–1191.
- Stoner E and Finasteride Study Group: Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 1994; 154: 83–88.
- Guess HA, Heyse JF, Gormley GJ: The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31–37.
- Rittmaster RS: Drug therapy: finasteride. N Engl J Med 1994; 330: 120–125.